Osteosarcoma is a highly aggressive primary bone malignancy with incompletely defined mechanisms underlying metabolic reprogramming. The study reports that ubiquitin-specific protease 16 (USP16) functions as a critical oncogenic driver in osteosarcoma by sustaining mitochondrial respiration and cell proliferation. Bioinformatics showed elevated USP16 in osteosarcoma tissues associated with worse prognosis. Functional assays indicated that USP16 depletion suppressed proliferation, colony formation, and subcutaneous xenograft growth, while USP16 overexpression promoted proliferation. Seahorse extracellular flux analysis revealed that USP16 loss drastically impaired mitochondrial oxygen consumption rate (OCR) and other oxidative phosphorylation (OXPHOS) parameters. Mechanistically, USP16 was found to deubiquitinate and stabilize estrogen-related receptor alpha (ESRRA), maintaining mitochondrial respiration. Re-expression of ESRRA in USP16-knockout cells rescued proliferation and respiratory defects, and pharmacologic inhibition of OXPHOS negated USP16-driven hyperproliferation. The authors propose the USP16/ESRRA deubiquitination axis as a promising therapeutic target in osteosarcoma.
Bioinformatics analysis in the study identified that USP16 is markedly upregulated in osteosarcoma tissues versus controls. Elevated USP16 expression was reported to predict poorer patient prognosis. The abstract does not specify the datasets, cohorts, or bioinformatics methods used, nor the statistical metrics supporting the prognostic association; those details were not provided in the supplied text.
Functional studies described in the abstract demonstrate that depletion of USP16 significantly suppressed osteosarcoma cell proliferation and reduced colony formation in vitro. In vivo, USP16 depletion impaired subcutaneous xenograft tumor growth. Conversely, forced overexpression of USP16 enhanced osteosarcoma cell proliferation. The work also observed associated downregulation of cell cycle regulators upon USP16 loss. Specific experimental parameters—such as the identity of cell lines, number of biological replicates, timing, and quantitative effect sizes—are not reported in the abstract and thus are not summarized here.
Seahorse extracellular flux analysis was used to assess mitochondrial function. USP16 depletion was reported to drastically reduce mitochondrial oxygen consumption rate (OCR) and impair other parameters of OXPHOS, demonstrating that USP16 supports mitochondrial respiratory activity in osteosarcoma cells. The abstract does not include the precise Seahorse metrics (basal respiration, ATP-linked respiration, maximal respiration, spare respiratory capacity), nor the experimental conditions or controls, so those details are not available from the provided source.
Mechanistic experiments indicated that USP16 sustains mitochondrial respiration through direct action on estrogen-related receptor alpha (ESRRA). USP16 reportedly deubiquitinates ESRRA, leading to its stabilization. This stabilization is presented as the molecular basis by which USP16 promotes mitochondrial OXPHOS and, consequently, osteosarcoma cell proliferation. The abstract does not detail the biochemical assays, ubiquitination sites, co-immunoprecipitation data, or direct binding evidence; such methodological specifics were not reported in the supplied text.
The study tested whether ESRRA restoration could compensate for USP16 loss. Ectopic expression of ESRRA in USP16-knockout cells effectively rescued both the suppressed proliferative phenotype and mitochondrial respiratory defects, indicating ESRRA is a key downstream effector of USP16. Additionally, pharmacologic inhibition of OXPHOS abolished the hyperproliferation driven by USP16 overexpression, supporting the functional importance of mitochondrial respiration in the USP16-driven phenotype. The abstract does not name the OXPHOS inhibitors used, their concentrations or dosing regimens, or the precise experimental design; these details were not provided in the source text.
Collectively, the findings indicate that the USP16/ESRRA deubiquitination axis contributes to osteosarcoma progression by promoting mitochondrial oxidative phosphorylation, and the axis is proposed as a potential therapeutic target. Two intervention strategies are implied by the results: targeting USP16 to reduce ESRRA stabilization and suppress OXPHOS-dependent tumor growth, or directly disrupting ESRRA activity or mitochondrial respiration. Specific candidate inhibitors of USP16 or ESRRA, preclinical efficacy data beyond the described assays, and safety considerations are not available in the abstract.
The abstract communicates major findings but omits many experimental details required to fully appraise the work. Absent details include datasets and methods for the bioinformatics analyses, the identities and numbers of human tissue samples, the cell lines and mouse models used, sample sizes and statistical analysis, assay parameters for Seahorse experiments, molecular details of the USP16–ESRRA interaction, and the identities/doses of OXPHOS inhibitors. The provided source text did not include these methodological and quantitative specifics.
The study identifies USP16 as an oncogenic promoter in osteosarcoma that enhances tumor progression by deubiquitinating and stabilizing ESRRA, thereby sustaining mitochondrial OXPHOS and cell proliferation. Restoration of ESRRA rescues defects caused by USP16 loss, and pharmacologic OXPHOS inhibition counters USP16-driven hyperproliferation. The authors highlight the USP16/ESRRA axis as a promising therapeutic target; further details and validation studies would be necessary to translate these findings toward clinical application.